The University of Aberdeen has officially opened its next-generation Field Cycling Imaging (FCI) whole-body medical imaging system, marking a fundamental disruption to standard MRI technology and promising to transform diagnosis across multiple areas of medicine.

The unveiling of the Hall Family Imaging Suite builds on a globally recognised legacy that began in the 1980s. Under the leadership of Professor John Mallard and Professor Jim Hutchison, the University of Aberdeen pioneered the world’s first whole-body MRI scanner. Crucially, they developed “spin-warp” imaging—the standard algorithm still used today by tens of thousands of MRI machines worldwide to assemble images without distortion.

While the global trajectory of MRI development over the last four decades has raced toward stronger, fixed magnetic fields to achieve higher anatomical resolution, Aberdeen researchers took a different path. They began exploring variable magnetic fields in the 1990s, culminating in the design of the newly commissioned FCI Mk-II system by Emeritus Professor David Lurie and Principal Investigator Dr. Lionel Broche.

Standard global MRI scanners are permanently locked into one massive magnetic field, capturing a single type of contrast based on water density. The Aberdeen FCI scanner, however, actively changes its magnetic field strength during the scan itself, sweeping from standard strengths down to fractions of a millitesla in a split second.

This rapid cycling reveals entirely new information about the human body. By operating at ultra-low fields, the scanner can detect slow molecular dynamics, such as how water molecules interact with the rigid protein structures of tissues. At specific ultra-low magnetic fields, the magnetic frequency of water protons perfectly matches the resonance of nitrogen atoms within proteins. This alignment creates a quantum energy transfer that the FCI scanner detects, providing a direct, non-invasive map of protein concentrations, tissue acidity, and fluid dynamics.

While standard high-field MRI excels at generating sub-millimeter anatomical pictures, it remains blind to these subtle molecular interactions. The FCI scanner currently operates with an in-plane spatial resolution of approximately 3 millimeters, but its true power lies in its spectral resolution. Rather than just producing a picture of anatomy, each 3-millimeter area contains a rich spectrum of quantitative data about the tissue’s molecular microenvironment. This capability allows clinicians to detect early disease markers—such as the breakdown of cartilage in osteoarthritis, fibrotic collagen in the heart, or the micro-environmental shifts in tumors—long before anatomical structures physically degrade.

Since late 2025, the new scanner has been utilised in four clinical research studies focusing on acute stroke, brain health, cardiac fibrosis, and brain cancer. Three additional studies launching later in 2026 will explore breast cancer, knee osteoarthritis, and glioblastoma, representing £2.82 million in research funding for its inaugural year.

“The FCI team exemplifies the University’s Aberdeen 2040 strategy: interdisciplinary collaboration, real-world impact, and innovation that benefits society,” stated Professor Peter Edwards, Principal and Vice-Chancellor of the University of Aberdeen. “This is a truly historic achievement and signifies a new frontier in medical imaging.”

The seven-year construction of the Mk-II system was made possible through University investment, major grant funding, and philanthropic support from organisations including the Mary Jamieson Hall & John F. Hall Trust and The Wolfson Foundation.

As the only operational human-scale FCI prototypes in the world, the Aberdeen systems stand alone in clinical diagnostics, cementing the University’s position not just as the birthplace of whole-body MRI, but as the architect of its next major evolution.